Real-world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study

被引：2

作者：

Mansilla-Polo, Miguel ^{[1
,2
]}

Pons-Benavent, Marti ^{[3
]}

Fernandez-Crehuet, Pablo ^{[4
]}

Vilarrasa, Eva ^{[5
]}

Albanell-Fernandez, Cristina ^{[6
]}

Morales-Tedone, Enrico ^{[6
]}

Rausell-Felix, Francisca ^{[6
]}

Alcala-Garcia, Rebeca ^{[7
]}

Matellanes-Palacios, Maria ^{[7
]}

Martin-Ezquerra, Gemma ^{[8
]}

Alfageme, Fernando ^{[9
]}

Ciudad-Blanco, Cristina ^{[10
]}

Lopez-Villaescusa, Maria Teresa ^{[11
]}

Garbayo-Salmons, Patricia ^{[12
]}

Martorell, Antonio ^{[13
]}

Escutia-Munoz, Begona ^{[1
,2
]}

Navarro-Blanco, Fernando ^{[1
,2
]}

Martin-Torregrosa, Daniel ^{[1
,2
]}

Cuenca-Barrales, Carlos ^{[14
]}

Molina-Leyva, Alejandro ^{[14
]}

Botella-Estrada, Rafael ^{[1
,2
,15
]}

机构：

[1] Hosp Univ & Politecn La Fe, Dept Dermatol, 106 Ave Fernando Abril Martorell, Valencia 46026, Spain

[2] Inst Invest Sanitaria IIS La Fe, Valencia, Spain

[3] Hosp Virgen Lirios, Dept Dermatol, Alicante, Spain

[4] Hosp Reina Sofia, Dept Dermatol, Cordoba, Spain

[5] Hosp Santa Creu St Pau, Dept Dermatol, Barcelona, Spain

[6] Hosp Clin Univ, Dept Dermatol, Valencia, Spain

[7] Hosp Sagunto, Dept Dermatol, Valencia, Spain

[8] Hosp Mar, Dept Dermatol, Barcelona, Spain

[9] Hosp Univ Puerta Hierro, Dept Dermatol, Madrid, Spain

[10] Hosp Univ Gregorio Maranon, Dept Dermatol, Madrid, Spain

[11] Complejo Hosp Univ Albacete, Dept Dermatol, Albacete, Spain

[12] Hosp Parc Tauli Sabadell, Dept Dermatol, Barcelona, Spain

[13] Hosp Manises, Dept Dermatol, Valencia, Spain

[14] Hosp Univ Virgen Nieves, Dept Dermatol, Granada, Spain

[15] Univ Valencia, Fac Med, Valencia, Spain

来源：

AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2024年 / 65卷 / 07期

关键词：

bimekizumab; biologic therapy; effectiveness; hidradenitis suppurativa; safety;

D O I：

10.1111/ajd.14339

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

In this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient-reported outcomes at week 16, including a notable decrease in mean IHS4 from 27.1 to 15.6 (p < 0.001), HS-PGA from 5.1 to 3.2 (p < 0.001), VAS pain from 8.3 to 4.7 (p < 0.001) and DLQI from 21.6 to 12.6 (p < 0.001). Bimekizumab, administered every 2 or 4 weeks, was well-tolerated with no discontinuations and no new safety concerns identified. These findings corroborate the drug's effectiveness and favourable safety profile observed in phase 3 clinical trials, supporting its use in real-world clinical practice for treating HS.

引用

页码：e198 / e202

页数：5

共 50 条

[21] Real-World, Observational, Retrospective Study to Evaluate the Effectiveness and Safety of Treatment with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Csipak, Angelica Richart
da Fonseca, Leonardo G.
Lopez, Rossana Veronica Mendoza
Estevez-Diz, Maria Del Pilar
CURRENT ONCOLOGY, 2024, 31 (11) : 6778 - 6790
[22] Effectiveness and safety of anti-TNF therapy for ankylosing spondylitis: a real-world study
Komel Pimenta, Pedro Ricardo
Ribeiro da Silva, Michael Ruberson
Ribeiro dos Santos, Jessica Barreto
Kakehasi, Adriana Maria
Assis Acurcio, Francisco de
Alvares-Teodoro, Juliana
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (06) : 509 - 517
[23] Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study
Rimke, Alexander
Sood, Siddhartha
Rankin, Brian D.
Abduelmula, Abrahim
Georgakopoulos, Jorge R.
Maliyar, Khalad
Bagit, Ahmed
Leung, Fernejoy
Stark, Lauren A.
Vender, Ronald
Yeung, Jensen
Prajapati, Vimal H.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (02) : 359 - 361
[24] Real-World Effectiveness of Lanadelumab in Hereditary Angioedema: Multicountry INTEGRATED Observational Study
Magerl, Markus
Bouillet, Laurence
Martinez-Saguer, Inmaculada
Gavini, Francois
Bent-Ennakhil, Nawal
Sayegh, Laura
Andresen, Irmgard
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2025, 13 (02) : 378 - 387.e2
[25] Real-world effectiveness of tofacitinib in patients with rheumatoid arthritis: a prospective observational study
Shouval, A.
Lidar, M.
Reitblat, T.
Zisman, D.
Balbir-Gurman, A.
Mashiach, T.
Almog, R.
Elkayam, O.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (06) : 1378 - 1384
[26] Metabolic Disorders/Obesity Is a Primary Risk Factor in Hidradenitis Suppurativa: An Immunohistochemical Real-World Approach
Kaleta, Katarzyna P.
Nikolakis, Georgios
Hossini, Amir M.
Balthasar, Ottfried
Almansouri, Daifallah
Vaiopoulos, Aristeidis
Knolle, Jurgen
Boguslawska, Anna
Wojas-Pelc, Anna
Zouboulis, Christos C.
DERMATOLOGY, 2022, 238 (02) : 251 - 259
[27] Long-term efficacy and safety of bimekizumab in real-world setting: a 52-week prospective study
Potestio, Luca
Ruggiero, Angelo
Martora, Fabrizio
Megna, Matteo
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2024, 317 (01)
[28] Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with Secukinumab: A Real-World Study
Haselgruber, Sofia
Fernandez-Crehuet-Serrano, Pablo
Fernandez-Ballesteros, Maria Dolores
Padial-Gomez, Alicia
Hernandez-Rodriguez, Juan Carlos
Ortiz-alvarez, Juan
Navarro-Guillamon, Pedro
Membrive-Jimenez, Cristina
Cuenca-Barrales, Carlos
Molina-Leyva, Alejandro
DERMATOLOGY AND THERAPY, 2024, 14 (07) : 1875 - 1890
[29] Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence
Parikh, Raunak
Singer, David
Chmielewski-Yee, Elizabeth
Dessart, Christophe
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (03)
[30] Long-Term Safety and Effectiveness of Diquafosol for the Treatment of Dry Eye in a Real-World Setting: A Prospective Observational Study
Yuichi Ohashi
Masahiro Munesue
Jun Shimazaki
Etsuko Takamura
Norihiko Yokoi
Hitoshi Watanabe
Akio Nomura
Fumiki Shimada
Advances in Therapy, 2020, 37 : 707 - 717

← 1 2 3 4 5 →